227. Osler disease
49 clinical trials, 69 drugs (DrugBank: 21 drugs), 23 drug target genes, 132 drug target pathways
Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04646356 (ClinicalTrials.gov) | October 20, 2020 | 20/10/2020 | Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed | Drug: Tacrolimus capsule (low-dose);Drug: Placebo | St. Michael's Hospital, Toronto | United States Department of Defense | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Canada |
| 2 | EUCTR2018-004179-11-DE (EUCTR) | 12/08/2020 | 12/03/2020 | The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber disease) patients who suffer fromgastrointestinal bleeding. | Effectiveness of Somatostatin Analogues in Patients with hereditaryhemorrhagic telangiectasia and symptomatic gastrointestinal bleeding,the SAIPAN-trial: a multicenter, randomized, open-label, parallel-group,superiority trial. - SAIPAN-trial | Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease (in specific patients with gastrointestinalbleedings);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Other descriptive name: OCTREOTIDE ACETATE | Radboudumc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 38 | Phase 3 | France;Netherlands;Germany;United Kingdom;Italy | ||
| 3 | NCT04113187 (ClinicalTrials.gov) | June 23, 2020 | 27/9/2019 | Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Hereditary Hemorrhagic Telangiectasia;Osler Weber Rendu Disease | Drug: Propranolol treatment;Drug: Placebo | University Hospital, Bordeaux | AMRO-HHT-France - Association Maladie de Rendu-Osler | Recruiting | 18 Years | N/A | All | 38 | Phase 3 | France |
| 4 | NCT04404881 (ClinicalTrials.gov) | May 2020 | 22/5/2020 | Bevacizumab In Hereditary Hemorrhagic Telangiectasia | A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia | Drug: Bevacizumab | Hanny Al-Samkari, MD | NULL | Not yet recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 5 | EUCTR2019-003585-40-NL (EUCTR) | 17/12/2019 | 30/09/2019 | Tacrolimus for bleeding in hereditary hemorrhagic telangiectasia patients | An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia - Tacrolimus for bleeding in HHT patients | Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by mucocutaneous telangiectasis. Telangiectasis predominantly observed in the nasal mucosa and gut, and are abnormal, thin walled blood vessel that can easily rupture leading to hemorrhage. MedDRA version: 20.0;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | St. Antonius Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Netherlands | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2019-002593-31-FR (EUCTR) | 05/11/2019 | 05/09/2019 | Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICURE | Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseA national, randomized, multicenter phase II studyEPICURE | Hereditary Hemorrhagic Telangiectasia MedDRA version: 20.1;Level: LLT;Classification code 10019887;Term: Hereditary hemorrhagic telangiectasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: OFEV Product Name: nintédanib Other descriptive name: NINTEDANIB | Hospices Civils de Lyon | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | France | ||
| 7 | NCT04139018 (ClinicalTrials.gov) | October 20, 2019 | 23/10/2019 | Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia | Efficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled Trial | Hereditary Hemorrhagic Telangiectasia | Drug: Timolol Gel;Drug: Placebo Gel | Washington University School of Medicine | NULL | Recruiting | 20 Years | N/A | All | 30 | Phase 2 | United States |
| 8 | NCT03910244 (ClinicalTrials.gov) | October 17, 2019 | 8/4/2019 | Pomalidomide for the Treatment of Bleeding in HHT | Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia | Telangiectasia, Hereditary Hemorrhagic | Drug: Pomalidomide Oral Product;Drug: Placebo oral capsule | The Cleveland Clinic | RTI International | Active, not recruiting | 18 Years | 99 Years | All | 2 | Phase 2 | United States |
| 9 | NCT03850730 (ClinicalTrials.gov) | September 2019 | 12/2/2019 | Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia | An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Pazopanib | Cure HHT | University of North Carolina | Not yet recruiting | 18 Years | 75 Years | All | 30 | Phase 1;Phase 2 | NULL |
| 10 | NCT03850964 (ClinicalTrials.gov) | September 2019 | 12/2/2019 | Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia | Randomized Double Blind Study to Evaluate the Effect of Low Dose Pazopanib on Bleeding Due to Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed;Anemia | Drug: Pazopanib;Drug: Placebo oral capsule | Cure HHT | NULL | Not yet recruiting | 18 Years | 75 Years | All | 45 | Phase 2;Phase 3 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2018-004179-11-NL (EUCTR) | 03/06/2019 | 14/05/2019 | The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding. | Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial. - SAIPAN-trial | Hereditary hemorrhagic telangiectasia (HHT);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Radboudumc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 38 | Phase 3 | Netherlands | |||
| 12 | NCT03397004 (ClinicalTrials.gov) | September 12, 2018 | 21/11/2017 | Doxycycline for Hereditary Hemorrhagic Telangiectasia | Doxycycline Crossover Trial for Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Doxycycline Hyclate;Drug: Placebo | St. Michael's Hospital, Toronto | Barrow Neurological Institute;Duke University;Feinstein Institute for Medical Research;University of Pittsburgh;Sunnybrook Health Sciences Centre | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Canada |
| 13 | NCT03981562 (ClinicalTrials.gov) | July 16, 2018 | 24/5/2019 | Vitamin D and Hereditary Haemorrhagic Telangiectasia | Vitamin D Supplementation and Reduction of Severity and Frequency of Epistaxis in Hereditary Haemorrhagic Telangiectasia | Hereditary Haemorrhagic Telangiectasia | Drug: Vit D;Drug: Placebo Oral Tablet | St. Paul's Hospital, Canada | NULL | Recruiting | 19 Years | N/A | All | 60 | Phase 2 | Canada |
| 14 | NCT03572556 (ClinicalTrials.gov) | June 28, 2018 | 8/6/2018 | Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT) | Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia | Biological: Blood samples;Other: Epistaxis charts | Centre Hospitalier Universitaire Dijon | NULL | Completed | 18 Years | N/A | All | 60 | France | |
| 15 | EUCTR2017-003272-31-NL (EUCTR) | 18/05/2018 | 11/01/2018 | Itraconazole as treatment for severe nose bleeding in patients with hereditary hemorrhagic telangiectasia | Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia - Itraconazole for epistaxis in HHT patients | Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850 MedDRA version: 20.0;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Sporanox Product Name: Itraconazole | St. Antonius Ziekenhuis | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 25 | Phase 2 | Netherlands | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | ChiCTR1900027420 | 2018-01-01 | 2019-11-12 | genetic screening for hereditary hemorrhagic telangiectasia | Investigation and applyling on the genetic screening kit for hereditary hemorrhagic telangiectasia | hereditary hemorrhagic telangiectasia | Gold Standard:Clinical outcomes;Index test:To identified the pathogenic variant through genetic testing for the coding region of ENG, ACVRL1, SMAD4 and BMP9.; | Beijing Institute of Otolaryngology | NULL | Recruiting | Both | Target condition:54;Difficult condition:0 | China | |||
| 17 | NCT02963129 (ClinicalTrials.gov) | June 2017 | 9/8/2016 | Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT | Treatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis. | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Mupirocin;Other: Placebo | Hospital Italiano de Buenos Aires | NULL | Not yet recruiting | 18 Years | N/A | Both | 40 | Phase 3 | Argentina |
| 18 | EUCTR2017-001031-39-FR (EUCTR) | 19/05/2017 | 19/06/2020 | BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT) | BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study. - BABH | Hemorrhagic Hereditary Telangiectasia MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: AVASTIN Product Name: BEVACIZUMAB INN or Proposed INN: BEVACIZUMAB | Hospices Civils de Lyon | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 3 | France | ||
| 19 | EUCTR2016-003982-24-ES (EUCTR) | 16/03/2017 | 09/12/2016 | Study to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeks | A phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeks | Hereditary hemorrhagic telangiectasia MedDRA version: 19.0;Level: LLT;Classification code 10020023;Term: HHT;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Asociación HHT España | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 2;Phase 4 | Spain | |||
| 20 | NCT02874326 (ClinicalTrials.gov) | October 2016 | 17/8/2016 | Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber | An Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal Bleeding | Hereditary Hemorrhagic Telangiectasia;Gastrointestinal Hemorrhage;Anemia | Drug: Octreotide LAR | Radboud University | St. Antonius Hospital | Unknown status | 18 Years | N/A | All | 15 | Phase 2 | Netherlands |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2016-001340-19-NL (EUCTR) | 21/07/2016 | 11/07/2016 | The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding due to Rendu-Osler-Weber disease. | An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROW | Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia);Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Sandostatin LAR 20 mg Product Name: Sandostatin LAR Product Code: RVG 18236 | Radboud University Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Netherlands | |||
| 22 | NCT02638012 (ClinicalTrials.gov) | December 2015 | 13/10/2015 | Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT) | Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT);Epistaxis | Drug: Floseal;Other: Packing | St. Michael's Hospital, Toronto | The Ottawa Hospital | Completed | 18 Years | N/A | All | 8 | N/A | Canada |
| 23 | NCT02484716 (ClinicalTrials.gov) | June 2015 | 17/6/2015 | Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO) | Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus Placebo | Hemorrhagic Hereditary Telangiectasia (HHT) | Drug: Timolol nasal spray;Drug: Placebo nasal spray | Hospices Civils de Lyon | NULL | Completed | 18 Years | N/A | All | 58 | Phase 2 | France |
| 24 | EUCTR2015-000385-55-FR (EUCTR) | 12/05/2015 | 29/03/2017 | Essai d’efficacité du timolol en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler. | TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler.Essai randomisé en double insu contre placebo - TEMPO | Rendu-Osler disease MedDRA version: 19.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Timolol Alcon 0.5% collyre Other descriptive name: TIMOLOL MALEATE | Hospices Civils de Lyon | NULL | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France | ||
| 25 | NCT02287558 (ClinicalTrials.gov) | January 27, 2015 | 6/11/2014 | Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study | A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia | Hereditary Hemorrhagic Telangiectasia;Idiopathic Vascular Ectasia | Drug: Pomalidomide | The Cleveland Clinic | NULL | Completed | 18 Years | N/A | All | 9 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02157987 (ClinicalTrials.gov) | December 15, 2014 | 4/6/2014 | Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose | Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose | Telangiectasia, Hereditary Hemorrhagic | Drug: bevacuzimab spray | University Hospital, Caen | NULL | Recruiting | 18 Years | 70 Years | All | 30 | Phase 1;Phase 2 | France |
| 27 | NCT02389959 (ClinicalTrials.gov) | August 4, 2014 | 11/3/2015 | Intranasal Bevacizumab for HHT-Related Epistaxis | Intranasal Bevacizumab for HHT-Related Epistaxis | HHT;Hereditary Hemorrhagic Telangiectasia;Epistaxis;Nose Bleeds;Nasal Bleeding | Drug: Bevacizumab;Drug: Placebo (Saline) | Stanford University | NULL | Completed | 18 Years | N/A | All | 40 | Phase 4 | United States |
| 28 | NCT02106520 (ClinicalTrials.gov) | April 2014 | 1/4/2014 | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Bevacizumab;Drug: placebo | Hospices Civils de Lyon | NULL | Terminated | 18 Years | N/A | Both | 80 | Phase 2;Phase 3 | France |
| 29 | EUCTR2013-004204-19-FR (EUCTR) | 26/02/2014 | 16/06/2015 | Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler | Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler - ALEGORI | Rendu-Osler disease MedDRA version: 18.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Avastin Product Name: Avastin INN or Proposed INN: BEVACIZUMAB | Hospices Civils de Lyon | NULL | Not Recruiting | Female: yes Male: yes | France | ||||
| 30 | NCT01908543 (ClinicalTrials.gov) | July 2013 | 23/7/2013 | Iron Deficiency and Hereditary Haemorrhagic Telangiectasia | Iron Deficiency and Hereditary Haemorrhagic Telangiectasia | Hereditary Haemorrhagic Telangiectasia | Drug: Ferrous sulphate 200mg oral tablet | Imperial College London | NULL | Terminated | 18 Years | 80 Years | All | 3 | N/A | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT01752049 (ClinicalTrials.gov) | May 2013 | 14/12/2012 | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Hereditary Hemorrhagic Telangiectasia | Drug: Topical timolol maleate;Drug: placebo saline drops | St. Michael's Hospital, Toronto | University of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 18 Years | N/A | All | 5 | N/A | Canada |
| 32 | NCT01485224 (ClinicalTrials.gov) | November 2011 | 28/11/2011 | Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia | Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Thalidomide | IRCCS Policlinico S. Matteo | NULL | Completed | 18 Years | N/A | All | 31 | Phase 2 | Italy |
| 33 | EUCTR2011-004096-36-IT (EUCTR) | 11/10/2011 | 19/03/2012 | Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasia | Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT) | Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia MedDRA version: 14.1;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: THALIDOMIDE CELGENE*28CPS 50MG INN or Proposed INN: THALIDOMIDE | OSPEDALE POLICLINICO S. MATTEO | NULL | Not Recruiting | Female: yes Male: yes | 31 | Phase 2 | Italy | ||
| 34 | NCT01507480 (ClinicalTrials.gov) | October 2011 | 6/12/2011 | The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia | The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia. | Hemorrhagic Hereditary Telangiectasia | Drug: Bevacizumab | Hospices Civils de Lyon | NULL | Completed | 18 Years | N/A | Both | 42 | Phase 1 | France |
| 35 | NCT01408030 (ClinicalTrials.gov) | August 2011 | 1/8/2011 | North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | North American Study of Epistaxis in HHT (NOSE) | Telangiectasia, Hereditary Hemorrhagic;Epistaxis | Drug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic Acid | James Gossage | HHT Foundation International | Completed | 18 Years | N/A | All | 123 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01406639 (ClinicalTrials.gov) | July 2011 | 29/7/2011 | Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Ranibizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT);Nosebleeds | Drug: Ranibizumab | University of California, San Diego | Genentech, Inc. | Withdrawn | 18 Years | N/A | Both | 0 | Phase 1 | United States |
| 37 | NCT01314274 (ClinicalTrials.gov) | March 2011 | 9/3/2011 | Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia | HHT;Morbus Osler;Epistaxis | Drug: Bevacizumab;Drug: NaCl | Medical University of Vienna | NULL | Completed | 18 Years | 80 Years | Both | 15 | Phase 2 | Austria |
| 38 | NCT01408732 (ClinicalTrials.gov) | February 2011 | 1/7/2011 | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Epistaxis;Hereditary Hemorrhagic Telangiectasia | Drug: Sclerotherapy;Other: Standard Treatment | University of Minnesota | American Rhinologic Society | Completed | 18 Years | N/A | All | 18 | Phase 1;Phase 2 | United States |
| 39 | EUCTR2009-018049-19-AT (EUCTR) | 13/12/2010 | 23/11/2010 | A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT | A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT | epistaxis | Trade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung INN or Proposed INN: BEVACIZUMAB Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Other descriptive name: SODIUM CHLORIDE | Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten | NULL | Not Recruiting | Female: yes Male: yes | 30 | Austria | |||
| 40 | NCT01402531 (ClinicalTrials.gov) | July 22, 2010 | 19/7/2011 | Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Submucosal Bevacizumab | University of California, San Diego | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT01397695 (ClinicalTrials.gov) | June 2009 | 18/7/2011 | Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Bevacizumab | University of California, San Diego | NULL | Completed | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 42 | EUCTR2008-006755-44-FR (EUCTR) | 15/01/2009 | 17/03/2009 | METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE | METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE | Maladie de Rendu-Osler MedDRA version: 9.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease | Trade Name: AVASTIN Product Name: AVASTIN INN or Proposed INN: BEVACIZUMAB Other descriptive name: SUB16402MIG | HOSPICES CIVILS DE LYON | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | France | |||
| 43 | EUCTR2010-020545-26-IT (EUCTR) | 09/12/2008 | 10/09/2010 | BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND | BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND | HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) MedDRA version: 9.1;Level: SOC;Classification code 10005329 | Trade Name: AVASTIN INN or Proposed INN: Bevacizumab Trade Name: AVASTIN INN or Proposed INN: Bevacizumab Trade Name: AVASTIN INN or Proposed INN: Bevacizumab | AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 44 | NCT00588146 (ClinicalTrials.gov) | January 2007 | 26/12/2007 | Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia | Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia | Anemia;Liver Disease;Hypoxemia | Drug: Pegylated Interferon Alpha2b;Other: Standard care | Mayo Clinic | Augusta University;St. Michael's Hospital, Toronto;Schering-Plough | Terminated | 18 Years | 70 Years | All | 10 | Phase 2 | United States |
| 45 | NCT00389935 (ClinicalTrials.gov) | October 2006 | 17/10/2006 | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena | Drug: Thalidomide | Northport Veterans Affairs Medical Center | Georgia Regents University;University of Massachusetts, Worcester | Completed | 18 Years | N/A | Both | 14 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT00375622 (ClinicalTrials.gov) | February 2005 | 12/9/2006 | Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial | Hereditary Hemorrhagic Telangiectasia | Drug: Tamoxifen | Rabin Medical Center | NULL | Completed | 18 Years | N/A | Both | 60 | Phase 2 | Israel | |
| 47 | NCT01031992 (ClinicalTrials.gov) | March 2002 | 11/12/2009 | Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia | Drug: Tranexamic acid first, than placebo;Drug: First placebo, than Tranexamic acid. | University Hospital, Saarland | Pharmacia GmbH, Erlangen, Germany;Baxter Healthcare Corporation | Completed | 18 Years | N/A | Both | 23 | Phase 3 | Germany |
| 48 | NCT00004654 (ClinicalTrials.gov) | January 1996 | 24/2/2000 | Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia | Drug: soy protein isolate | National Center for Research Resources (NCRR) | Yale University | Completed | 15 Years | N/A | Both | 60 | Phase 3 | NULL | |
| 49 | NCT00004327 (ClinicalTrials.gov) | January 1995 | 18/10/1999 | Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia | Hereditary Hemorrhagic Telangiectasia;Ectasia | Drug: octreotide | National Center for Research Resources (NCRR) | Yale University | Completed | N/A | N/A | Both | 8 | Phase 2 | NULL |